# A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

> **NCT00917267** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 691 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** exenatide once weekly
- **DRUG:** exenatide twice daily

## Key facts

- **NCT ID:** NCT00917267
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-09
- **Final completion:** 2011-04
- **Target enrollment:** 691 (ACTUAL)
- **Last updated:** 2015-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00917267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00917267, "A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00917267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*